Trabecular bone score (TBS) may be an effective, indirect measurement of bone quality in patients with type 2 diabetes (T2D), according to research presented at the 2017 World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, which took place March 23-26, 2017, in Florence, Italy.
Researchers from Brussels, Belgium, conducted a cross-sectional analysis of patients with T2D to determine how a diabetes diagnosis has an impact on patients’ bone mineral density (BMD) and influences future fracture risk.
Participants were pulled from the FRISBEE study — an ongoing, prospective epidemiological study of a population-based cohort located in Brussels, Belgium; 260 out of 3560 postmenopausal women were included in the researchers’ analysis.
All participants had baseline dual-energy X-ray absorptiometry (DXA) scans. Two groups were created: participants with T2D (n=65) and participants without T2D (n=195) serving as controls. TBS was calculated for all participants based on lumbar spine DXA examination.
Mean age was similar in both groups (69.9±5.8 years in the T2D group and 69.8±5.6 in the control groups); fracture risk scores (FRAX) were also similar (9.5±6.7 and 9.9±6.7, respectively).
While the investigators found no significant difference in mean T score values, mean TBS was significantly lower in the T2D group vs the control group (1.185±0.172; 95% CI, 1.14-1.22 vs 1.267±0.132; 95% CI, 1.24-1.28; P =.005).
“Despite similar DXA values, we found a lower TBS score in diabetic compared with nondiabetic subjects,” the researchers concluded.
“These results are in line with the current view that [type 2 diabetes] induces microarchitectural deteriorations of bone tissue. Moreover, our data suggest that TBS may be a useful tool in the assessment of bone quality in T2DM.”
Baleanu F, Bergmann P, Hambye AS, et al. Assessment of bone quality with trabecular bone score (TBS) in type 2 diabetes mellitus (T2DM). Abstract P832. Presented at: 2017 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. March 23-26, 2017; Florence, Italy.